Pfizer has followed its rival Merck and agreed a licensing deal with the UN-backed Medicines Patent Pool to expand low-cost access to its Covid-19 antiviral pill throughout the developing world.
The agreement marks the first time the US pharmaceutical company has agreed to share the technology behind a Covid-19 medical product, in contrast to its refusal to license its vaccine to generic manufacturers.
The royalty-free deal with the MPP should boost global supplies of Pfizer’s antiviral pill, which cut the risk of hospitalisation and death from the virus by almost 90 per cent in late-stage trials.
您已阅读17%（604字），剩余83%（2923字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。